Time is Brain Secures €3 Million and Achieves CE/MDR Approval to Accelerate the Adoption of Real-Time Stroke Intelligence Across Europe

Funding and regulatory approval pave the way for European commercialization through strategic distribution partnerships.

Barcelona, Spain – 10th July 2026 – Time is Brain, pioneering the emerging category of Real-Time Stroke Intelligence, today announced two major milestones supporting its commercial expansion across Europe: the successful closing of an oversubscribed €3 million Pre-Series A financing round and CE/MDR approval for its flagship Real-Time Stroke Intelligence platform.

Together, these achievements represent a significant step forward in the company’s mission to help clinicians make faster, more informed stroke decisions through continuous neurological assessment and real-time clinical insight.

The financing will support commercial expansion, distributor onboarding, market access activities and continued clinical evidence generation as Time is Brain prepares for the European rollout of its platform later this year.

Stroke affects more than 10 million people worldwide every year and remains one of the leading causes of death and long-term disability. Every minute of delayed treatment increases the risk of irreversible brain injury. While imaging technologies have transformed stroke diagnosis and treatment, many clinical decisions still rely on information captured at a single point in time.

Time is Brain was founded on the belief that clinicians need more than snapshots—they need continuous neurological insight when every second matters.

“Stroke is one of the few medical emergencies where every minute directly influences a patient’s future. Yet clinicians often make critical decisions using information captured at a single moment in time,”said Dr. Alicia Martinez, neurologist, Co-Founder and CEO of Time is Brain. “We believe the future of stroke care will combine imaging with continuous neurological intelligence, helping clinicians make faster, more informed decisions when every second matters. CE/MDR approval and this investment allow us to bring that vision into clinical practice across Europe.”

From Snapshots to Real-Time Stroke Intelligence

For decades, stroke care has relied on episodic assessment supported by imaging technologies such as CT and MRI. These tools remain fundamental to diagnosis, but they provide information captured at a single point in time.

Time is Brain believes the next evolution of stroke care is not replacing imaging—it is complementing imaging with continuous neurological assessment that provides clinicians with real-time clinical insight throughout the patient journey.

This shift represents the transition from snapshots to Real-Time Stroke Intelligence, enabling healthcare professionals to make faster, more informed decisions across pre-hospital triage, emergency assessment and in-hospital treatment.

Creating a New Category

Time is Brain is creating a new category: Real-Time Stroke Intelligence.

By transforming brain activity into actionable clinical insight, the company’s platform enables clinicians to continuously assess neurological function throughout the stroke care pathway. Through continuous neurological assessment and AI-driven neurodiagnostics, clinicians gain additional information to support faster, more informed treatment decisions when time is critical.

Real-Time Stroke Intelligence complements today’s imaging-based standard of care by providing continuous neurological assessment that supports clinical decision-making across the entire stroke pathway.

The company’s first commercial platform, BraiN20®, has been developed to integrate seamlessly into existing stroke workflows while complementing established imaging techniques. The platform supports clinicians across three critical stages of care:

·       Pre-hospital stroke triage
·       Emergency department assessment
·       In-hospital treatment and monitoring

“Imaging remains fundamental to stroke care, but it provides only part of the clinical picture,” said Dr. Antoni Dávalos, Co-Founder and Chief Scientific Officer of Time is Brain. “Continuous assessment of brain function offers complementary information that can support treatment decisions throughout the patient journey. This is the clinical foundation of Real-Time Stroke Intelligence.”

Expanding Across Europ

Following CE/MDR approval, Time is Brain is preparing the commercial introduction of BraiN20® across Europe beginning later this year.

To support this commercial expansion, the company has established a global network of more than 50 stroke Key Opinion Leaders (KOLs) and clinical champions and continues to engage clinicians worldwide who are ready to become early adopters and join us in redefining the future of stroke diagnosis and prognosis.

Time is Brain is seeking partners with established relationships in stroke care, emergency medicine and neurology who share its vision of advancing Real-Time Stroke Intelligence and introducing this new approach to stroke assessment across three key clinical settings:

·       Pre-hospital stroke triage
·       Emergency department assessment
·       In-hospital treatment and monitoring

Hospitals, healthcare providers, stroke networks and distributors interested in collaborating with Time is Brain are invited to contact the company to explore partnership opportunities.

As healthcare systems increasingly seek solutions that improve clinical decision-making while reducing treatment delays, Time is Brain believes Real-Time Stroke Intelligence will become an essential complement to modern stroke care.

Time is Brain remains committed to transforming neurocritical care through innovation, precision, and collaboration.